Download PDF
Semin Thromb Hemost
DOI: 10.1055/s-0044-1787725
Review Article

Laboratory Testing for Fibrinogen Disorders: From Routine Investigations to Research Studies

Anetta Undas
1   Department of Thromboembolic Diseases, Institute of Cardiology, Jagiellonian University Medical College, and Center for Research and Medical Technology, St. John Paul II Hospital, Cracow, Poland
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Congenital and acquired fibrinogen disorders often have heterogeneous clinical phenotypes and are challenging from a laboratory perspective. Fibrinogen determination using the Clauss method remains the gold standard, while the reproducibility and significance of the thrombin time and the reptilase time are limited. Molecular testing for causative mutations in fibrinogen genes is now recommended to confirm the diagnosis of congenital fibrinogen disorders. Research assays are used to evaluate alterations to fibrin formation and properties of plasma and purified fibrinogen-derived clots, characterized by fiber thickness, the number of branches, and pore sizes. Fibrin clot permeability (permeation, porosity) using a hydrostatic pressure system represents the most commonly used method for evaluating fibrin network density. Reduced clot permeability, which denotes the reduced size of an average pore in the network, results in tighter fibrin networks, typically associated with impaired susceptibility to lysis, leading to a thrombotic tendency. Biophysical properties of fibrin clots are largely assessed using rheometry, with atomic force microscopy and nanorheology being increasingly used in disease states. Thromboelastography and thromboelastometry, a simple modification of rheometry, have been used, mainly in intensive care units, for more than 50 years. Given growing evidence for altered fibrin clot properties in diseases with elevated risk of venous and arterial thromboembolism and in some bleeding disorders, further work on standardization and validation of the assessment of fibrin clot characteristics is needed. This review summarizes the current methods used to evaluate fibrinogen abnormalities in both diagnostic and research laboratories.

Keywords

fibrinogen - fibrin - permeability - thromboelastography - rheometry


Publication History

Article published online:
18 June 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers
333 Seventh Avenue, New York, NY 10001, USA.

 

  • References

  • 1 Weisel JW, Litvinov RI. Mechanisms of fibrin polymerization and clinical implications. Blood 2013; 121 (10) 1712-1719
    CrossrefPubMedGoogle Scholar
  • 2 Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost 2005; 3 (08) 1894-1904
    CrossrefPubMedGoogle Scholar
  • 3 de Moerloose P, Neerman-Arbez M. Congenital fibrinogen disorders. Semin Thromb Hemost 2009; 35 (04) 356-366
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Casini A, Moerloose P, Neerman-Arbez M. One hundred years of congenital fibrinogen disorders. Semin Thromb Hemost 2022; 48 (08) 880-888
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Casini A. From routine to research laboratory: strategies for the diagnosis of congenital fibrinogen disorders. Hamostaseologie 2020; 40 (04) 460-466
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Cunningham MT, Brandt JT, Laposata M, Olson JD. Laboratory diagnosis of dysfibrinogenemia. Arch Pathol Lab Med 2002; 126 (04) 499-505
    CrossrefPubMedGoogle Scholar
  • 7 Besser MW, MacDonald SG. Acquired hypofibrinogenemia: current perspectives. J Blood Med 2016; 7: 217-225
    CrossrefPubMedGoogle Scholar
  • 8 Verhovsek M, Moffat KA, Hayward CP. Laboratory testing for fibrinogen abnormalities. Am J Hematol 2008; 83 (12) 928-931
    CrossrefPubMedGoogle Scholar
  • 9 Undas A. How to assess fibrinogen levels and fibrin clot properties in clinical practice?. Semin Thromb Hemost 2016; 42 (04) 381-388
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Mackie IJ, Kitchen S, Machin SJ, Lowe GD. Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology. Guidelines on fibrinogen assays. Br J Haematol 2003; 121 (03) 396-404
    CrossrefPubMedGoogle Scholar
  • 11 Mackie I, Casini A, Pieters M, Pruthi R, Reilly-Stitt C, Suzuki A. International council for standardisation in haematology recommendations on fibrinogen assays, thrombin clotting time and related tests in the investigation of bleeding disorders. Int J Lab Hematol 2024; 46 (01) 20-32
    CrossrefPubMedGoogle Scholar
  • 12 Miesbach W, Schenk J, Alesci S, Lindhoff-Last E. Comparison of the fibrinogen Clauss assay and the fibrinogen PT derived method in patients with dysfibrinogenemia. Thromb Res 2010; 126 (06) e428-e433
    CrossrefPubMedGoogle Scholar
  • 13 De Cristofaro R, Landolfi R. Measurement of plasma fibrinogen concentration by the prothrombin-time-derived method: applicability and limitations. Blood Coagul Fibrinolysis 1998; 9 (03) 251-259
    CrossrefPubMedGoogle Scholar
  • 14 Jensen T, Halvorsen S, Godal HC, Sandset PM, Skjøonsberg OH. Discrepancy between fibrinogen concentrations determined by clotting rate and clottability assays during the acute-phase reaction. Thromb Res 2000; 100 (05) 397-403
    CrossrefPubMedGoogle Scholar
  • 15 Undas A. Determination of fibrinogen and thrombin time (TT). Methods Mol Biol 2017; 1646: 105-110
    CrossrefPubMedGoogle Scholar
  • 16 Karapetian H. Reptilase time (RT). Methods Mol Biol 2013; 992: 273-277
    CrossrefPubMedGoogle Scholar
  • 17 Walter S, Stabler S, Lefkowitz JB. Fibrinogen Denver: a dysfibrinogenemia associated with an abnormal reptilase time and significant bleeding. Haemophilia 2006; 12 (04) 393-397
    CrossrefPubMedGoogle Scholar
  • 18 Pieters M, Philippou H, Undas A, de Lange Z, Rijken DC, Mutch NJ. Subcommittee on Factor XIII and Fibrinogen, and the Subcommittee on Fibrinolysis. An international study on the feasibility of a standardized combined plasma clot turbidity and lysis assay: communication from the SSC of the ISTH. J Thromb Haemost 2018; 16 (05) 1007-1012
    CrossrefPubMedGoogle Scholar
  • 19 Blombäck B, Carlsson K, Fatah K, Hessel B, Procyk R. Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation. Thromb Res 1994; 75 (05) 521-538
    CrossrefPubMedGoogle Scholar
  • 20 Blombäck B, Carlsson K, Hessel B, Liljeborg A, Procyk R, Aslund N. Native fibrin gel networks observed by 3D microscopy, permeation and turbidity. Biochim Biophys Acta 1989; ;9971–2: 96-110
    CrossrefPubMedGoogle Scholar
  • 21 Ząbczyk M, Undas A. Plasma fibrin clot structure and thromboembolism: clinical implications. Pol Arch Intern Med 2017; 127 (12) 873-881
    CrossrefPubMedGoogle Scholar
  • 22 Carr Jr ME, Shen LL, Hermans J. Mass-length ratio of fibrin fibers from gel permeation and light scattering. Biopolymers 1977; 16 (01) 1-15
    CrossrefPubMedGoogle Scholar
  • 23 Blombäck B, Okada M. Fibrin gel structure and clotting time. Thromb Res 1982; 25 (1-2): 51-70
    CrossrefPubMedGoogle Scholar
  • 24 Wolberg AS. Thrombin generation and fibrin clot structure. Blood Rev 2007; 21 (03) 131-142
    CrossrefPubMedGoogle Scholar
  • 25 Ząbczyk M, Ariëns RAS, Undas A. Fibrin clot properties in cardiovascular disease: from basic mechanisms to clinical practice. Cardiovasc Res 2023; 119 (01) 94-111
    CrossrefPubMedGoogle Scholar
  • 26 Pieters M, Undas A, Marchi R, De Maat MP, Weisel J, Ariëns RA. Factor XIII And Fibrinogen Subcommittee Of The Scientific Standardisation Committee Of The International Society For Thrombosis And Haemostasis. An international study on the standardization of fibrin clot permeability measurement: methodological considerations and implications for healthy control values. J Thromb Haemost 2012; 10 (10) 2179-2181
    CrossrefPubMedGoogle Scholar
  • 27 Ząbczyk M, Piłat A, Awsiuk M, Undas A. An automated method for fibrin clot permeability assessment. Blood Coagul Fibrinolysis 2015; 26 (01) 104-109
    CrossrefPubMedGoogle Scholar
  • 28 Collet JP, Montalescot G, Lesty C. et al. Disaggregation of in vitro preformed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysis. Arterioscler Thromb Vasc Biol 2001; 21 (01) 142-148
    CrossrefPubMedGoogle Scholar
  • 29 Blombäck M, He S, Bark N, Wallen HN, Elg M. Effects on fibrin network porosity of anticoagulants with different modes of action and reversal by activated coagulation factor concentrate. Br J Haematol 2011; 152 (06) 758-765
    CrossrefPubMedGoogle Scholar
  • 30 Zalewski J, Bogaert J, Sadowski M. et al. Plasma fibrin clot phenotype independently affects intracoronary thrombus ultrastructure in patients with acute myocardial infarction. Thromb Haemost 2015; 113 (06) 1258-1269
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Ryan EA, Mockros LF, Weisel JW, Lorand L. Structural origins of fibrin clot rheology. Biophys J 1999; 77 (05) 2813-2826
    CrossrefPubMedGoogle Scholar
  • 32 Collet JP, Allali Y, Lesty C. et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol 2006; 26 (11) 2567-2573
    CrossrefPubMedGoogle Scholar
  • 33 Evans PA, Hawkins K, Williams PR. Rheometry for blood coagulation studies. Rheol Rev 2006; 255-291
    PubMedGoogle Scholar
  • 34 Solomon C, Schöchl H, Ranucci M, Schött U, Schlimp CJ. Comparison of fibrin-based clot elasticity parameters measured by free oscillation rheometry (ReoRox ®) versus thromboelastometry (ROTEM ®). Scand J Clin Lab Invest 2015; 75 (03) 239-246
    CrossrefPubMedGoogle Scholar
  • 35 Feller T, Kellermayer MS, Kiss B. Nano-thrombelastography of fibrin during blood plasma clotting. J Struct Biol 2014; 186 (03) 462-471
    CrossrefPubMedGoogle Scholar
  • 36 Allan P, Uitte de Willige S, Abou-Saleh RH, Connell SD, Ariëns RA. Evidence that fibrinogen γ′ directly interferes with protofibril growth: implications for fibrin structure and clot stiffness. J Thromb Haemost 2012; 10 (06) 1072-1080
    CrossrefPubMedGoogle Scholar
  • 37 Baker SR, Zabczyk M, Macrae FL, Duval C, Undas A, Ariëns RAS. Recurrent venous thromboembolism patients form clots with lower elastic modulus than those formed by patients with non-recurrent disease. J Thromb Haemost 2019; 17 (04) 618-626
    CrossrefPubMedGoogle Scholar
  • 38 Evans PA, Hawkins K, Morris RH. et al. Gel point and fractal microstructure of incipient blood clots are significant new markers of hemostasis for healthy and anticoagulated blood. Blood 2010; 116 (17) 3341-3346
    CrossrefPubMedGoogle Scholar
  • 39 Davies NA, Harrison NK, Morris RH. et al. Fractal dimension (df) as a new structural biomarker of clot microstructure in different stages of lung cancer. Thromb Haemost 2015; 114 (06) 1251-1259
    Article in Thieme ConnectPubMedGoogle Scholar
  • 40 Lawrence MJ, Sabra A, Mills G. et al. A new biomarker quantifies differences in clot microstructure in patients with venous thromboembolism. Br J Haematol 2015; 168 (04) 571-575
    CrossrefPubMedGoogle Scholar
  • 41 Luddington RJ. Thrombelastography/thromboelastometry. Clin Lab Haematol 2005; 27 (02) 81-90
    CrossrefPubMedGoogle Scholar
  • 42 Hans GA, Besser MW. The place of viscoelastic testing in clinical practice. Br J Haematol 2016; 173 (01) 37-48
    CrossrefPubMedGoogle Scholar
  • 43 Chitlur M, Sorensen B, Rivard GE. et al. Standardization of thromboelastography: a report from the TEG-ROTEM working group. Haemophilia 2011; 17 (03) 532-537
    CrossrefPubMedGoogle Scholar
  • 44 Quarterman C, Shaw M, Johnson I, Agarwal S. Intra- and inter-centre standardisation of thromboelastography (TEG®). Anaesthesia 2014; 69 (08) 883-890
    CrossrefPubMedGoogle Scholar
  • 45 Harr JN, Moore EE, Ghasabyan A. et al. Functional fibrinogen assay indicates that fibrinogen is critical in correcting abnormal clot strength following trauma. Shock 2013; 39 (01) 45-49
    CrossrefPubMedGoogle Scholar
  • 46 Carroll RC, Craft RM, Chavez JJ, Snider CC, Kirby RK, Cohen E. Measurement of functional fibrinogen levels using the thrombelastograph. J Clin Anesth 2008; 20 (03) 186-190
    CrossrefPubMedGoogle Scholar
  • 47 Galanakis DK, Neerman-Arbez M, Brennan S. et al. Thromboelastographic phenotypes of fibrinogen and its variants: clinical and non-clinical implications. Thromb Res 2014; 133 (06) 1115-1123
    CrossrefPubMedGoogle Scholar
  • 48 Szanto T, Lassila R, Lemponen M, Lehtinen E, Neerman-Arbez M, Casini A. Whole blood thromboelastometry by ROTEM and thrombin generation by Genesia according to the genotype and clinical phenotype in congenital fibrinogen disorders. Int J Mol Sci 2021; 22 (05) 2286
    CrossrefPubMedGoogle Scholar